The present announcement does not concern the award of a public contract within the meaning of the procurement coordination directive (2014/24 / EU) or antitrust law. In the interests of the broadest possible information for interested pharmaceutical companies, this announcement is made in the supplement to the Official Journal of the European Union. The process designation "open process" (Section IV.1.1) used in the context of the present announcement text is owed to the specifications of the announcement form. This, as well as the use of the medium "TED", does not involve any submission to public procurement regulations, the validity of which is by law or procurement ordinances is not mandatory. It is a framework agreement with the option to join, which relates to various active ingredients.

The subject of the contract are drugs that contain the active ingredient 4-hydroxybutanoic acid.

The subject of the contract are drugs that contain the active ingredient colecalciferol in a prescription and oral, divided dosage form.

The subject of the contract are drugs that contain the active ingredient colecalciferol in a prescription-only and oral, non-divided dosage form

The subject of the contract are drugs that contain the active ingredient combination cromoglicic acid and reproterol

The subject of the contract are drugs that contain the active ingredient desfesoterodine

The subject of the contract are medicinal products that contain the active ingredient dexamethasone in the form of eye drops in single-dose pipettes.

The subject of the contract are drugs that contain the active ingredient diazepam in a parenteral and / or rectal dosage form.

The subject of the contract are drugs that contain the active ingredient eprosartan.

The subject of the contract are drugs that contain the active ingredient combination eprosartan and hydrochlorothiazide.

The subject of the contract are drugs that contain the active ingredient estradiol in a dermal dosage form (excluding PFT).

The subject of the contract are drugs that contain the active ingredient fentanyl in a nasal dosage form.

The subject of the contract are drugs that contain the active ingredient combination beclometasone, formoterol and glycopyrronium.

The subject of the contract are drugs that contain the active ingredient follitropin alfa.

The subject of the contract are medicinal products that contain the active ingredient fulvestrant in pack sizes of 1 and 4 units.

The subject of the contract are drugs that contain the active ingredient ganirelix.

The subject of the contract are drugs that contain the active ingredient haloperidol.

The subject of the contract are drugs that contain the active ingredient hydrocortisone in an unrestricted solid oral dosage form.

The subject of the contract are pharmaceuticals that contain the active ingredient hydrocortisone in a delayed solid oral dosage form.

The subject of the contract are drugs that contain the active ingredient ibandronic acid in the dosage forms FER and / or IFE.

The subject of the contract are drugs that contain the active ingredient lanreotide.

The subject of the contract are drugs that contain the active ingredient latanoprost in the dosage form of single-dose pipettes.

The subject of the contract are drugs that contain the active ingredient lenograstim.

The subject of the contract are drugs that contain the active ingredient Biperiden in a retarded oral dosage form.

The subject of the contract are drugs that contain the active ingredient leuprorelin.

The subject of the contract are medicinal products that contain the active ingredient levetiracetam in the granular form.

The subject of the contract are drugs that contain the active ingredient lipefilgrastim.

The subject of the contract are drugs that contain the active ingredient meloxicam.

The subject of the contract are drugs that contain the active ingredient combination olodaterol and tiotropium.

The subject of the contract are drugs that contain the active ingredient palonosetron in a solid oral dosage form.

The subject of the contract are drugs that contain the active ingredient pilocarpine in a solid oral dosage form.

The subject of the contract are drugs that contain the active ingredient prednicarbate.

The subject of the contract are drugs that contain the active ingredient raltegravir.

The subject of the contract are drugs that contain the active ingredient combination rosuvastatin and ezetimibe.

The subject of the contract are drugs that contain the active ingredient combination brinzolamide and brimonidine.

The subject of the contract are drugs that contain the active ingredient Sevelamer hydrochloride.

The subject of the contract are drugs that contain the active ingredient somatropin.

The subject of the contract are drugs that contain the active ingredient sumatriptan in a parenteral and / or nasal dosage form.

The subject of the contract are drugs that contain the active ingredient tapentadol.

The subject of the contract are drugs that contain the active ingredient tiotropium in the dosage form metered dose aerosol.

The subject of the contract are drugs that contain the active ingredient tocilizumab.

The subject of the contract are drugs that contain the active substance valproic acid in the dosage forms FTA, KMR and / or LSE.

The subject of the contract are drugs that contain the active ingredient zoledronic acid in a strength of 5 mg.

The subject of the contract are drugs that contain the active ingredient combination brinzolamide and timolol.

The subject of the contract are drugs that contain the active ingredient captopril.

The subject of the contract are drugs that contain the active ingredient ciprofloxacin in the dosage forms eye drops, ear drops and / or dry juice.

The subject of the contract are medicinal products that contain the active ingredient ciprofloxacin in the form of infusion solution.

The subject of the contract are drugs that contain the active ingredient clomipramine.